Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $839 | $112 | $15 |
| Gross Profit | -$839 | -$112 | -$15 |
| % Margin | – | – | – |
| R&D Expenses | $60,935 | $27,999 | $9,115 |
| G&A Expenses | $22,120 | $8,180 | $1,366 |
| SG&A Expenses | $22,120 | $8,068 | $1,366 |
| Sales & Mktg Exp. | $0 | -$112 | $0 |
| Other Operating Expenses | -$839 | $0 | -$129 |
| Operating Expenses | $82,216 | $36,067 | $10,352 |
| Operating Income | -$83,055 | -$36,179 | -$10,367 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $4,748 | $1,403 | -$285 |
| Pre-Tax Income | -$78,307 | -$34,776 | -$10,652 |
| Tax Expense | $0 | $10 | $0 |
| Net Income | -$78,307 | -$34,786 | -$10,652 |
| % Margin | – | – | – |
| EPS | -0.38 | -0.19 | -0.053 |
| % Growth | -100% | -258.5% | – |
| EPS Diluted | -0.38 | -0.19 | -0.053 |
| Weighted Avg Shares Out | 207,383 | 180,788 | 201,171 |
| Weighted Avg Shares Out Dil | 207,383 | 180,788 | 201,171 |
| Supplemental Information | – | – | – |
| Interest Income | $12,138 | $2,527 | $0 |
| Interest Expense | $0 | $0 | $285 |
| Depreciation & Amortization | $839 | $112 | $15 |
| EBITDA | -$77,468 | -$34,664 | -$10,352 |
| % Margin | – | – | – |